Argenx S.E

Argenx N.V. is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. Utilizing its suite of differentiated technologies, Co. is focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need.
  • TickerARGX
  • ISINNL0010832176
  • ExchangeEuronext Brussels
  • SectorPharmaceuticals & Biotechnology
  • CountryNetherlands

Analysts

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

1 director sold

A director at Argen X SE sold 10,000 shares at 123.580EUR and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board m...

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

1 director sold

A director at Argen X SE sold 10,000 shares at 123.580EUR and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board m...

Thanks to a better fundamental star rating, ARGENX SE sees an upgrade to Neutral

The independent financial analyst theScreener just awarded an improved star rating to ARGENX SE (BE), active in the Biotechnology industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 2 out of 4 possible stars. With regard to its market behaviour, it remains unchanged and can be qualified as moderately risky. theScreener considers that these elements allow slightly upgrading its rating to Neutral. As of the analysis date May 17, 2019, the closing price was EUR 115.70 and its expected value was estimated at EUR 110.41.

Valérie GASTALDY

Short term view - ARGENX SE : The trend is bullish.

The trend is bullish. Prices are making further progress. The targets are at €82.40 and then €94.80. The break of €58.50 would endanger the trend.

Valérie GASTALDY

Analyse court terme - ARGENX SE : La tendance est haussière.

La tendance est haussière. La progression des cours se poursuit. Les objectifs sont à 82,40 € puis 94,80 €. La rupture de 58,50 € mettrait la tendance en danger.

Valérie GASTALDY

Short term view - ARGENX SE : The background trend is clearly bearish.

The background trend is clearly bearish. Prices are falling again, but the movement has become hesitant. The next support is at €58.50. The background trend would be questioned should prices rise above €94.80.

Valérie GASTALDY

Analyse court terme - ARGENX SE : La tendance de fond est clairement orientée à la baisse.

La tendance de fond est clairement orientée à la baisse. Les prix baissent à nouveau, mais le mouvement est devenu hésitant. Le prochain support est à 58,50 €. La tendance de fond serait remise en cause en cas de franchissement de 94,80 €.

Jérôme VINERIER

Analyse moyen terme - ARGENX SE : La tendance est haussière.

La tendance est haussière. La progression des cours se poursuit. Les objectifs sont à 94,80 € puis 119,80 €. La rupture de 18,80 € mettrait la tendance en danger.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch